Journal of Cardiovascular Pharmacology and Therapeutics

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (OnlineFirst[PDF])
Right arrow All Versions of this Article:
1074248408316485v1
13/2/89    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Patel, S. S.
Right arrow Articles by Mascarenhas, D. A. N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, S. S.
Right arrow Articles by Mascarenhas, D. A. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
First published on April 15, 2008, doi:10.1177/1074248408316485

Journal of Cardiovascular Pharmacology and Therapeutics 2008;13:89.

A more recent version of this article appeared on June 1, 2008
 © 2008 SAGE Publications

Article

Intracoronary Abciximab Use in Patients Undergoing PCI at a Community Hospital: A Single Operator Experience

Sandeep S. Patel, MD, Hiralal Rana, MD, and Daniel A. N. Mascarenhas, MD, FACC, FSCAI*

* To whom correspondence should be addressed. E-mail: danmasc{at}rcn.com.


  Abstract
Objective: To evaluate the safety of intracoronary (IC) abciximab during percutaneous coronary intervention (PCI). Background: Adjunctive treatment with glycoprotein IIb/IIIa inhibitors, especially abciximab, during PCI has been shown to improve clinical and procedural outcomes in numerous studies. However, significant bleeding complications exist with its use and this has limited its standard use. Interest has grown in local (IC) use with studies showing safety and long-term effectiveness, especially in patients with high thrombus loads. Methods: A retrospective review of records in a database of patients who had PCI by a single operator at the Easton Hospital. Results: 611 patients received IC abciximab, and there were no complications in 610 (98.3%) patients; only 1 had an allergic reaction. Conclusions: IC abciximab is safe and has a unique role in the catheterization lab and in patients at high risk of bleeding complications who would benefit from its limited use.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?